<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871113</url>
  </required_header>
  <id_info>
    <org_study_id>207959</org_study_id>
    <nct_id>NCT04871113</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults</brief_title>
  <official_title>A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A, an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naïve HIV-1-Infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate antiviral activity, efficacy, safety, tolerability,&#xD;
      pharmacokinetics (PK) and pharmacodynamics (PD) of GSK3810109A in HIV-1 infected treatment&#xD;
      naive adults. Participants will receive a single dose of GSK3810109A administered either&#xD;
      intravenously (IV) or subcutaneously (SC). The study includes a screening phase, a randomized&#xD;
      monotherapy phase and a standard of care follow-up phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">November 8, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 8, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The is a sequential treatment, two-part study which will include a screening phase, a randomized monotherapy phase and a standard of care follow-up phase.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open-label study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum change from Baseline in plasma HIV-1 ribonucleic acid (RNA) levels (copies/milliliter)</measure>
    <time_frame>Baseline and up to Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to Week 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Grade 2-4 alanine aminotransferase (ALT) and aspartate aminotransferase (AST) abnormality</measure>
    <time_frame>Up to Week 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent abnormal electrocardiogram (ECG) findings</measure>
    <time_frame>Up to Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Grade 2-4 injection site reactions (ISR)</measure>
    <time_frame>Up to Day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC [0-t]) of GSK3810109A</measure>
    <time_frame>Up to Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of GSK3810109A</measure>
    <time_frame>Up to Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum observed plasma concentration (Tmax) of GSK3810109A</measure>
    <time_frame>Up to Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of GSK3810109A</measure>
    <time_frame>Up to Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Plasma HIV-1 RNA in relation to Cmax</measure>
    <time_frame>Baseline and up to Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Plasma HIV-1 RNA in relation to AUC</measure>
    <time_frame>Baseline and up to Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in cluster of differentiation 4 plus (CD4+) T cell counts (cells per cubic millimeters)</measure>
    <time_frame>Baseline and up to Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of CD4+ T cell counts</measure>
    <time_frame>Up to Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with positive anti-drug antibodies (ADAs) against GSK3810109A</measure>
    <time_frame>Up to Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers of ADAs against GSK3810109A</measure>
    <time_frame>Up to Week 60</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Part 1: Participants receiving GSK3810109A 40 mg/kg (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered GSK3810109A as a single IV infusion of 40 mg/kg dose in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Participants receiving GSK3810109A 280 mg/kg (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered GSK3810109A as a single IV infusion of 280 mg/kg dose in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Participants receiving GSK3810109A (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered GSK3810109A as a single IV infusion or SC injection and will include dose level determined based on the data of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Participants receiving GSK3810109A (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered GSK3810109A as a single IV infusion or SC injection and will include dose level determined based on the data of Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Participants receiving GSK3810109A (Cohort 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered GSK3810109A as a single IV infusion or SC injection and will include dose level determined based on the data of Part 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK3810109A</intervention_name>
    <description>GSK3810109A will be available as sterile aqueous solution.</description>
    <arm_group_label>Part 1: Participants receiving GSK3810109A 280 mg/kg (Cohort 2)</arm_group_label>
    <arm_group_label>Part 1: Participants receiving GSK3810109A 40 mg/kg (Cohort 1)</arm_group_label>
    <arm_group_label>Part 2: Participants receiving GSK3810109A (Cohort 3)</arm_group_label>
    <arm_group_label>Part 2: Participants receiving GSK3810109A (Cohort 4)</arm_group_label>
    <arm_group_label>Part 2: Participants receiving GSK3810109A (Cohort 5)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 18 to 65 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Participants must have HIV-1 infection within 45 days of the Screening Visit: Plasma&#xD;
             HIV-1 RNA greater than or equal to (&gt;=) 5000 copies/mL (c/mL).&#xD;
&#xD;
          -  Confirmed screening CD4+ T-cell count &gt;= 350 cells per cubic millimeter (cells/mm3).&#xD;
&#xD;
          -  Antiretroviral naïve: No Antiretroviral therapy (ARTs) (in combination or monotherapy)&#xD;
             received after the diagnosis of HIV-1 infection.&#xD;
&#xD;
          -  Body weight &gt;= 50 kg to less than or equal to (&lt;=) 115 kg.&#xD;
&#xD;
          -  Male and/or female. Contraceptive use by men or women should be consistent with local&#xD;
             regulations regarding the methods of contraception for those participating in clinical&#xD;
             studies. All participants participating in the study should be counselled on safer&#xD;
             sexual practices including the use and benefit/risk of effective barrier methods (e.g.&#xD;
             male condom) and on the risk of HIV transmission to an uninfected partner; a.&#xD;
             Participants who are female at birth are eligible to participate if at least one of&#xD;
             the following conditions applies: Not Pregnant or breastfeeding and at least one of&#xD;
             the following conditions applies: Is not a participant of childbearing potential&#xD;
             (POCBP). OR Is a POCBP and using an acceptable contraceptive method during the&#xD;
             intervention period (at a minimum until after the last dose of study intervention).&#xD;
             The investigator should evaluate the effectiveness of the contraceptive method in&#xD;
             relationship to the first dose of study intervention. A POCBP must have a negative&#xD;
             highly sensitive pregnancy test (urine or serum as required by local regulations) on&#xD;
             Day 1, prior to the first dose of study intervention. If a urine test cannot be&#xD;
             confirmed as negative (example [e.g.], an ambiguous result), a serum pregnancy test is&#xD;
             required. In such cases, the participant must be excluded from participation if the&#xD;
             serum pregnancy result is positive.&#xD;
&#xD;
          -  Corrected QT interval (QTc) Interval &lt;= 450 milliseconds (msec)&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with primary HIV infection, evidenced by acute retroviral syndrome (e.g.,&#xD;
             fever, malaise, fatigue, etc) and/or evidence of recent (within 3 months) documented&#xD;
             viremia without antibody production and/or evidence of recent (within 3 months)&#xD;
             documented seroconversion.&#xD;
&#xD;
          -  Participants who are pregnant, breastfeeding, plan to become pregnant or breastfeed&#xD;
             during the study.&#xD;
&#xD;
          -  The participant has an underlying skin disease or disorder (example i.e. infection,&#xD;
             inflammation, dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy,&#xD;
             urticaria) that would interfere with assessment of injection sites.&#xD;
&#xD;
          -  Known history of cirrhosis with or without viral hepatitis co-infection.&#xD;
&#xD;
          -  History of clinically relevant hepatitis within last 6 months.&#xD;
&#xD;
          -  Evidence of Hepatitis B virus (HBV) infection based on the results of testing at&#xD;
             screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody&#xD;
             (anti-HBc), Hepatitis B surface antigen antibody (anti-HBs) and HBV Deoxyribonucleic&#xD;
             acid (DNA) as follows: Participants positive for HBsAg are excluded; Participants&#xD;
             negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive&#xD;
             for HBV DNA are excluded. Participants negative for anti-HBs but positive for anti-HBc&#xD;
             (negative HBsAg status) and negative for HBV DNA are not excluded.&#xD;
&#xD;
          -  Participants with Hepatitis C co-infection.&#xD;
&#xD;
          -  Untreated syphilis infection (positive rapid plasma reagin [RPR] at screening) without&#xD;
             documentation of treatment. Participants who are one month post completed treatment&#xD;
             are eligible if recruitment is open.&#xD;
&#xD;
        Rescreening is allowed after treatment.&#xD;
&#xD;
          -  Prior receipt of licensed or investigational monoclonal antibody.&#xD;
&#xD;
          -  Any evidence of an active Centers for Disease Control and Prevention (CDC) Stage 3&#xD;
             disease except cutaneous Kaposi's sarcoma not requiring systemic therapy.&#xD;
&#xD;
          -  Known or suspected moderate or severe hepatic impairment (Class C as determined by&#xD;
             Child-Pugh Classification) coagulopathy, hypoalbuminemia, esophageal or gastric&#xD;
             varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the&#xD;
             exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  Clinically significant cardiovascular disease, as defined by history/evidence of&#xD;
             congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery&#xD;
             bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty&#xD;
             (PTCA) or any clinically significant cardiac disease at the discretion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or&#xD;
             resected, non-invasive cutaneous squamous cell carcinoma, or cervical, anal or penile&#xD;
             intraepithelial neoplasia; other localized malignancies require agreement between the&#xD;
             investigator and the study medical monitor for inclusion of the participant prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Any pre-existing physical or mental condition which, in the opinion of the&#xD;
             investigator, may interfere with the participant's ability to comply with the dosing&#xD;
             schedule and/or protocol evaluations, or which may compromise the safety of the&#xD;
             participant.&#xD;
&#xD;
          -  Participants with substance abuse disorders or social restraints that the investigator&#xD;
             considers to be possible deterrents to successful completion of the study.&#xD;
&#xD;
          -  Participants who in the investigator's judgment, pose a significant suicidality risk.&#xD;
             Participants' history of suicidal behavior and/or suicidal ideation should be&#xD;
             considered when evaluating for suicide risk.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications or their components or drugs of&#xD;
             their class, or a history of drug or other allergy that, in the opinion of the&#xD;
             investigator or Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Any condition which, in the opinion of the investigator, may interfere with the&#xD;
             absorption, distribution, metabolism or excretion of the study drugs, combination ART&#xD;
             or render the participant unable to take oral medication.&#xD;
&#xD;
          -  Participants with a positive Corona Virus Disease 2019 (COVID-19) test at Screening.&#xD;
             Participants with known COVID-19 positive contacts within the past 14 days, or with&#xD;
             symptoms suggestive of active COVID-19 (fever, cough, myalgias, shortness of breath,&#xD;
             loss of taste or smell), should be excluded. Participants who remain symptom-free for&#xD;
             at least 14 days after a COVID-19 exposure are allowed.&#xD;
&#xD;
          -  Has received any HIV-1 immunotherapeutic vaccine or prophylactic vaccine.&#xD;
&#xD;
          -  Treatment with any of the following agents within 28 days of screening: radiation&#xD;
             therapy; cytotoxic chemotherapeutic agents; any systemic immune suppressant;&#xD;
&#xD;
          -  Exposure to an experimental drug or experimental vaccine within either 28 days, 5&#xD;
             half-lives of the test agent, or twice the duration of the biological effect of the&#xD;
             test agent, whichever is longer, prior to the first dose of IP.&#xD;
&#xD;
          -  Participants receiving any prohibited medication and who are unwilling or unable to&#xD;
             switch to an alternate medication.&#xD;
&#xD;
          -  Participant enrolled in a prior or concurrent clinical study that includes a drug&#xD;
             intervention within the last 30 days.&#xD;
&#xD;
          -  Any acute laboratory abnormality at Screening, which, in the opinion of the&#xD;
             investigator, would preclude the participant's inclusion in the study of an&#xD;
             investigational compound.&#xD;
&#xD;
          -  Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during&#xD;
             the Screening period to verify a result.&#xD;
&#xD;
          -  ALT &gt;= 3 times the upper limit of normal (ULN).&#xD;
&#xD;
          -  Creatinine clearance of &lt;50 mL/minute/1.73 meter^2) via Chronic Kidney Disease&#xD;
             Epidemiology Collaboration (CKD-EPI) method.&#xD;
&#xD;
          -  The participant has a tattoo or other dermatological condition overlying potential&#xD;
             injection sites which may interfere with interpretation of injection site reactions or&#xD;
             administration of GSK3810109A.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Schneider</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>William J. Towner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Peter J Ruane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Charlotte-Paige Rolle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Samir Gupta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Benson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph McGowan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mehri S McKellar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher J. Bettacchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marisa Sanchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1202ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pedro Cahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alejandro Ferro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000PBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sergio Lupo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan B Angel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sharon L. Walmsley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Benoit Trottier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4P 0W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander Wong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antiretroviral-naïve</keyword>
  <keyword>Broadly neutralizing antibody</keyword>
  <keyword>GSK3810109A</keyword>
  <keyword>HIV</keyword>
  <keyword>N6LS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

